SCHEMBL4666151

SCHEMBL4666151

O=S(=O)(Nc1ccc(Nc2cc(-c3ccc(F)cc3)ncn2)cc1)c1ccc(F)cc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 0.56
CYP2C19 P33261 5/20 0.56
CYP2D6 P10635 4/20 0.56
CYP3A4 P08684 4/20 0.56
USP2 O75604 3/20 0.56
CLK4 Q9HAZ1 3/20 0.56
MAPK1 P28482 2/20 0.56
ALDH1A1 P00352 2/20 0.56
ALOX15 P16050 2/20 0.56
HSD17B10 Q99714 2/20 0.56
CYP2C9 P11712 2/20 0.56
TP53 P04637 2/20 0.56
MEN1 O00255 1/20 0.56
GLA P06280 1/20 0.56
KMT2A Q03164 1/20 0.56
KIT P10721 1/20 0.52
ABL1 P00519 5/20 0.51
BCR P11274 5/20 0.51
PIK3CB P42338 1/20 0.47
RORC P51449 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4663770 0.90 USP2 (0.51) CYP1A2CYP2C19CYP2D6CYP3A4USP2
SCHEMBL4666113 0.90 ABL1 (0.49) CYP1A2CYP2C19CYP2D6CYP3A4USP2
SCHEMBL4663875 0.90 CYP1A2 (0.55) CYP1A2CYP2C19CYP2D6CYP3A4USP2
SCHEMBL4664376 0.86 PRF1 (0.56) CYP1A2CYP2C19CYP2D6CYP3A4USP2
SCHEMBL4664333 0.84 TP53 (0.49) CYP1A2CYP2C19CYP2D6CYP3A4USP2
SCHEMBL4665773 0.84 CYP1A2 (0.56) CYP1A2CYP2C19CYP2D6CYP3A4USP2
SCHEMBL4663866 0.84 PIK3C3 (0.48) TP53KITPIK3CBRORCPIK3C3
SCHEMBL4665707 0.83 CYP1A2 (0.55) CYP1A2CYP2C19CYP2D6CYP3A4USP2
SCHEMBL4665802 0.82 CYP1A2 (0.50) CYP1A2CYP2C19CYP2D6CYP3A4USP2
SCHEMBL4664319 0.82 ABL1 (0.46) CYP1A2CYP2C19CYP2D6CYP3A4USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 CYP1A2 1215/4885CYP2C19 961/4885CYP2D6 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.